Vitiligo
Methodology & AI Transparency ⓘ
Vitiligo Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Vitiligo causes white patches on your skin.
- 2 Real-world patient consensus: Clinical coding for Vitiligo uses ICD-10 L80 across Skin & Dermatology specialty care.
- 3 Typical cash cost range: Differential triage of Vitiligo (L80) utilizes or targeted biologics [Vitiligo L80].
- 4 Top reported side effects / signs: Objective lab/clinical target for Vitiligo: Fasting Lipids & in Vitiligo (L80: ALT (if systemic) (Within baseline reference limits (L80)) and 25-Hydroxy Vitamin D in Vitiligo (L80: & hs-CRP).
Ask our AI Specialists anything about Vitiligo
What Is Vitiligo?
Vitiligo causes white patches on your skin. It can also affect your eyes, mouth, and nose. It occurs when the cells that give your skin its color are destroyed. No one knows what destroys them. It is more common in people with autoimmune diseases, and it might run in families. It usually starts before age 40. The white patches are more common where your skin is exposed to the sun. In some cases, the patches spread. Vitiligo can cause your hair to gray early. If you have dark skin, you may lose color inside your mouth. Using sunscreen will help protect your skin, and cosmetics can cover up the patches. Treatments for vitiligo include medicines, light therapy, and surgery.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Vitiligo (ICD-10 L80) is driven by cutaneous immune skewing in Vitiligo (L80: (Th2/IL-4/IL-13 in atopic); Cross-referenced with NIH MeSH (Vitiligo), specialists in Dermatology: Acne, Eczema, Psoriasis & Rosacea monitor 25-Hydroxy Vitamin D in Vitiligo (L80: & hs-CRP) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Vitiligo (L80): recurrent flares triggered in Vitiligo (L80: by UV exposure,)
- • Secondary Vitiligo clinical sign: persistent erythematous plaques, in Vitiligo (L80: scaly patches, pruritic)
- • Symptom flares in Vitiligo correlating with Fasting Lipids & in Vitiligo (L80: ALT (if systemic) deviation outside Within baseline reference limits (L80)
- • Functional skin & dermatology impact requiring or targeted biologics [Vitiligo L80] evaluation (L80)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Vitiligo Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L80 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Fasting Lipids & in Vitiligo (L80: ALT (if systemic) | Within baseline reference limits (L80) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Vitiligo (L80: & hs-CRP) | 25(OH)D 40–65 ng/mL (L80) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Affected Body Surface in Vitiligo (L80: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L80) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Vitiligo
Treatment selection for Vitiligo depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Vitiligo)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of microencapsulated benzoyl peroxide and microencapsulated: What a 571-Participant Study Found E-BPO/T provided statistically significant and clinically relevant improvements in IGA and inflammatory and noninflammatory lesion counts and was well tolerated in subjects with moderate to severe acne. Journal of the American Academy of Dermatology • 2023-10-15 • Phase III Randomized Trial | N = 571 | 93/100 | PMID 37356627 ↗ |
| Can This Approach Help? Inside the Latest Research on Fixed-dose combination Cal/BD foam on the work productivity of patients with Fixed-dose combination Cal/BD foam used for long-term management of psoriasis significantly reduces psoriasis-related work productivity and activity impairment which may result in substantial indirect cost savings. Journal of the European Academy of Dermatology and Venereology : JEADV • 2022-07-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35297108 ↗ |
| Managing Hair loss Areata: Can Immune-Mediated Disorders Make a Real Difference? (What New Research Reveals) These findings confirm that AA is associated with a heightened risk of various immune-mediated conditions. International journal of dermatology • 2025-11-15 • Meta-Analysis | Multi-cohort | 86/100 | PMID 40603702 ↗ |
| What the Latest Evidence Really Says About Heterogeneity in Depression and Suicidality Risk Among Vitiligo Vitiligo is significantly associated with elevated risks of depression and suicidality. Stress and health : journal of the International Society for the Investigation of Stress • 2026-12-15 • Meta-Analysis | Multi-cohort | 86/100 | PMID 42952473 ↗ |
| What the Latest Evidence Really Says About Selenium levels and skin diseases: systematic review and Selenium levels were associated with several skin diseases and the disease severity, and high selenium levels tended to be a protective factor in certain skin diseases. Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) • 2020-12-15 • Meta-Analysis | Multi-cohort | 86/100 | PMID 32497930 ↗ |
Vitiligo Patient Community & “People Like Me” Threads
Filter Vitiligo community threads and patient logs by age, biological sex, dosage, and treatment duration.